BR112015023161A8 - derivados de piridin-4-ila - Google Patents

derivados de piridin-4-ila

Info

Publication number
BR112015023161A8
BR112015023161A8 BR112015023161A BR112015023161A BR112015023161A8 BR 112015023161 A8 BR112015023161 A8 BR 112015023161A8 BR 112015023161 A BR112015023161 A BR 112015023161A BR 112015023161 A BR112015023161 A BR 112015023161A BR 112015023161 A8 BR112015023161 A8 BR 112015023161A8
Authority
BR
Brazil
Prior art keywords
pyridin
derivatives
compounds
formula
preparation
Prior art date
Application number
BR112015023161A
Other languages
English (en)
Other versions
BR112015023161A2 (pt
BR112015023161B1 (pt
Inventor
Steiner Beat
Lescop Cyrille
Bolli Martin
Nayler Oliver
Original Assignee
Actelion Pharmaceuticals Ltd
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd, Idorsia Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of BR112015023161A2 publication Critical patent/BR112015023161A2/pt
Publication of BR112015023161A8 publication Critical patent/BR112015023161A8/pt
Publication of BR112015023161B1 publication Critical patent/BR112015023161B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Abstract

derivados de piridin-4-il a invenção diz respeito a compostos da fórmula (i), fórmula (i) em que r1 e r2 são descritos na descrição, sua preparação e seu uso como compostos ativos farmaceuticamente. ditos compostos particularmente agem como agentes imunomoduladores.
BR112015023161-6A 2013-03-15 2014-03-14 Derivados de piridin-4-ila BR112015023161B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13159482.2 2013-03-15
EP13159482 2013-03-15
PCT/IB2014/059794 WO2014141171A1 (en) 2013-03-15 2014-03-14 Pyridin-4-yl derivatives

Publications (3)

Publication Number Publication Date
BR112015023161A2 BR112015023161A2 (pt) 2017-07-18
BR112015023161A8 true BR112015023161A8 (pt) 2021-06-22
BR112015023161B1 BR112015023161B1 (pt) 2022-11-16

Family

ID=47877933

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015023161-6A BR112015023161B1 (pt) 2013-03-15 2014-03-14 Derivados de piridin-4-ila

Country Status (34)

Country Link
US (1) US9617250B2 (pt)
EP (1) EP2970236B1 (pt)
JP (1) JP6387361B2 (pt)
KR (1) KR102212975B1 (pt)
CN (1) CN105189487B (pt)
AR (1) AR095523A1 (pt)
AU (1) AU2014229217B2 (pt)
BR (1) BR112015023161B1 (pt)
CA (1) CA2900910C (pt)
CL (1) CL2015002620A1 (pt)
CY (1) CY1119619T1 (pt)
DK (1) DK2970236T3 (pt)
EA (1) EA029309B1 (pt)
ES (1) ES2649475T3 (pt)
HK (1) HK1220454A1 (pt)
HR (1) HRP20171763T1 (pt)
HU (1) HUE035154T2 (pt)
IL (1) IL241363B (pt)
LT (1) LT2970236T (pt)
MA (1) MA38482B1 (pt)
MX (1) MX363545B (pt)
MY (1) MY173573A (pt)
NO (1) NO2970236T3 (pt)
NZ (1) NZ713080A (pt)
PH (1) PH12015502118A1 (pt)
PL (1) PL2970236T3 (pt)
PT (1) PT2970236T (pt)
SA (1) SA515361104B1 (pt)
SG (1) SG11201507227UA (pt)
SI (1) SI2970236T1 (pt)
TW (1) TWI623534B (pt)
UA (1) UA115357C2 (pt)
WO (1) WO2014141171A1 (pt)
ZA (1) ZA201507657B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
EA035929B1 (ru) 2013-01-15 2020-09-02 Инсайт Холдингс Корпорейшн ТИАЗОЛКАРБОКСАМИДЫ И ПИРИДИНКАРБОКСАМИДЫ, ИСПОЛЬЗУЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Pim-КИНАЗЫ
SG11201601259YA (en) 2013-08-23 2016-03-30 Incyte Corp Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
MY192358A (en) 2015-05-20 2022-08-17 Idorsia Pharmaceuticals Ltd Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
WO2017004610A1 (en) * 2015-07-02 2017-01-05 Exelixis, Inc. Tercyclic s1p3-sparing, s1p1 receptor agonists
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7686891A (en) 1990-04-05 1991-10-30 American National Red Cross, The A protein family related to immediate-early protein expressed by human endothelial cells during differentiation
US6423508B1 (en) 1998-03-09 2002-07-23 Smithkline Beecham Corporation Polynucleotide sequences of human EDG-1c
AU2003279915A1 (en) 2002-10-15 2004-05-04 Merck And Co., Inc. Process for making azetidine-3-carboxylic acid
PL2069336T3 (pl) * 2006-09-07 2013-05-31 Idorsia Pharmaceuticals Ltd Pochodne pirydyn-4-ylu jako środki immunomodulujące
PL2069335T3 (pl) 2006-09-08 2013-05-31 Actelion Pharmaceuticals Ltd Pochodne pirydyn-3-ylu jako środki immunomodulujące
JP5250556B2 (ja) 2006-09-21 2013-07-31 アクテリオン ファーマシューティカルズ リミテッド フェニル誘導体及びそれらの免疫調節薬としての使用
JP2010521450A (ja) 2007-03-16 2010-06-24 アクテリオン ファーマシューティカルズ リミテッド Ｓ１ｐ１／ｅｄｇ１受容体アゴニストとしてのアミノ−ピリジン誘導体
BRPI0815190A2 (pt) 2007-08-17 2015-03-31 Actelion Pharmaceuticals Ltd Composto derivado de piridina, composição farmacêutica que o compreende e uso do mesmo
US8202865B2 (en) 2007-10-04 2012-06-19 Merck Serono Sa Oxadiazole derivatives
AR069146A1 (es) 2007-11-01 2009-12-30 Actelion Pharmaceuticals Ltd Derivados de pirimidina, composicion farmaceutica que los comprende y el uso de esta para el tratamiento de enfermedades relacionadas con la activacion del sistema inmunitario.
CN101965345B (zh) 2008-03-06 2014-05-28 埃科特莱茵药品有限公司 吡啶化合物
EP2262800A1 (en) 2008-03-06 2010-12-22 Actelion Pharmaceuticals Ltd. Novel pyrimidine-pyridine derivatives
AU2009220893A1 (en) 2008-03-07 2009-09-11 Actelion Pharmaceuticals Ltd Novel aminomethyl benzene derivatives
US8575200B2 (en) 2008-03-07 2013-11-05 Actelion Pharmaceuticals Ltd Pyridin-2-yl derivatives as immunomodulating agents
JP5837417B2 (ja) * 2008-05-14 2015-12-24 ザ スクリプス リサーチ インスティテュート スフィンゴシンリン酸受容体の新規なモジュレーター
US8791142B2 (en) 2009-03-03 2014-07-29 Merck Serono S.A. Oxazole pyridine derivatives useful as S1P1 receptor agonists
PT2454255E (pt) 2009-07-16 2014-01-14 Actelion Pharmaceuticals Ltd Derivados de piridin-4-il como agonistas de s1/p1/edg1
TW201120016A (en) 2009-12-08 2011-06-16 Abbott Lab Novel oxadiazole compounds
BR112013017923B1 (pt) 2011-01-19 2021-08-10 Idorsia Pharmaceuticals Ltd Derivados de 2-metóxi-piridin-4-il

Also Published As

Publication number Publication date
NO2970236T3 (pt) 2018-01-27
CN105189487B (zh) 2017-12-26
CA2900910A1 (en) 2014-09-18
CN105189487A (zh) 2015-12-23
KR102212975B1 (ko) 2021-02-05
SI2970236T1 (sl) 2017-11-30
IL241363B (en) 2018-11-29
ES2649475T3 (es) 2018-01-12
CY1119619T1 (el) 2018-04-04
AU2014229217A1 (en) 2015-11-05
DK2970236T3 (en) 2017-10-16
TWI623534B (zh) 2018-05-11
MX2015012293A (es) 2015-12-16
EA201500931A1 (ru) 2016-03-31
EP2970236A1 (en) 2016-01-20
US9617250B2 (en) 2017-04-11
BR112015023161A2 (pt) 2017-07-18
AR095523A1 (es) 2015-10-21
EA029309B1 (ru) 2018-03-30
MX363545B (es) 2019-03-27
LT2970236T (lt) 2017-11-10
HUE035154T2 (en) 2018-05-02
NZ713080A (en) 2020-06-26
UA115357C2 (uk) 2017-10-25
MY173573A (en) 2020-02-04
BR112015023161B1 (pt) 2022-11-16
PH12015502118B1 (en) 2016-01-25
US20160031866A1 (en) 2016-02-04
JP6387361B2 (ja) 2018-09-05
SA515361104B1 (ar) 2016-06-28
CA2900910C (en) 2021-03-30
PT2970236T (pt) 2017-11-30
WO2014141171A1 (en) 2014-09-18
MA38482B1 (fr) 2018-11-30
EP2970236B1 (en) 2017-08-30
KR20150128947A (ko) 2015-11-18
PL2970236T3 (pl) 2018-01-31
IL241363A0 (en) 2015-11-30
ZA201507657B (en) 2022-08-31
HK1220454A1 (zh) 2017-05-05
CL2015002620A1 (es) 2016-03-18
SG11201507227UA (en) 2015-10-29
MA38482A1 (fr) 2017-12-29
AU2014229217B2 (en) 2017-12-14
TW201443044A (zh) 2014-11-16
HRP20171763T1 (hr) 2017-12-29
JP2016512227A (ja) 2016-04-25
PH12015502118A1 (en) 2016-01-25

Similar Documents

Publication Publication Date Title
BR112015023161A8 (pt) derivados de piridin-4-ila
BR112016002459A8 (pt) Derivados de benzimidazolil-metil ureia como agonistas receptores de alx
BR112016026291A2 (pt) Derivados do ácido borônico e usos terapêuticos dos mesmos
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
CR20150250A (es) Nuevos derivados de piridina
CR20160076A (es) NUEVOS DERIVADOS DE TRIAZOLO[4,5-d]PIRIMIDINA
CO6680717A2 (es) Derivados de quinolina y quinoxalina como inhibidores de cinasa
BR112015023417A2 (pt) compostos heterocíclicos e seus usos
CR20150447A (es) Nuevos derivados de pirazol
CR20150427A (es) Sales de derivados de 2-amino-1-hidroxietil-8-hidroxiquinolin-2 (1h)-ona que tienen actividad agonista del receptor b2 adrenérgico así como actividad antagonista del receptor
BR112017016311A2 (pt) derivados de 9h-pirrolo-dipiridina
BR112015013124A2 (pt) novos derivados de piridina
BR112015013463A8 (pt) Derivados de carboxamida indol como antagonistas do receptor de p2x7
CR20150440A (es) Nuevos derivados de piridina
CR20150555A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina
SV2018005760A (es) Derivados de aminotiazol utiles como agentes antiviricos
CU20150061A7 (es) PIRIMIDO-[4,5-b]-QUINOLINA-4,5(3H,10H)-DIONAS COMO SUPRESORAS DE MUTACIÓN SIN SENTIDO
BR112015009603A2 (pt) novos derivados de pirazina
EA201400822A1 (ru) Производные гетероциклических амидов в качестве антагонистов p2xрецептора
CO7170173A2 (es) Derivados de carbamato/urea
CR20160083A (es) Compuestos con actividad pesticida
BR112014016803A8 (pt) amidas macrocíclicas como inibidoras de protease
EA201600123A1 (ru) Производные 1-(пиперазин-1-ил)-2-([1,2,4]триазол-1-ил)этанона
UA109804C2 (xx) 2-метоксипіридин-4-ільні похідні
BR112015030824A2 (pt) novos derivados de tetrazolona

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: ACTELION PHARMACEUTICALS LTD (CH)

B25C Requirement related to requested transfer of rights

Owner name: ACTELION PHARMACEUTICALS LTD (CH)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: IDORSIA PHARMACEUTICALS LTD (CH)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/03/2014, OBSERVADAS AS CONDICOES LEGAIS